

10/582973

Sheet 1 of 2

INFORMATION DISCLOSURE STATEMENT

AG2 Rec'd PCT/PTO 15 JUN 2008

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: June 15, 2006

ATTY DOCKET NO.
2006_0825ASERIAL NO.
NEWAPPLICANT
Toshikazu NAKAMURA et al.FILING DATE
June 15, 2006

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
/MA/	AB	93/23541	11/1993	WO			correspond to Ref. AC	
/MA/	AC	7-508420	9/1995	JP				NO
	AD							
	AE							
	AF							

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

/MA/	AG	R. Hofmann et al., "Scatter factor is a glycoprotein but glycosylation is not required for its activity," Biochim.Biophys..Act., 1992, 1120(3), pp. 343-350
	AH	K. Miyazawa et al., "Human hepatocyte growth factor (hHGF), mRNA, complete cds.," Database GenBank accession No.M29145, November 8, 1994 (11-8-94)
	AI	K. M. Weidner et al., "Evidence for the identity of human scatter factor and human hepatocyte growth factor.," Proc. Natl. Acad. Sci. U.S.A., August 1991, 88(16), pp. 7001-7005
	AJ	H. Hara et al., "Structural study of the N-linked oligosaccharies of hepatocyte growth factor by two-dimensional sugar mapping," J. Biochem. (Tokyo), 1993, Vol. 114, No. 1, pp. 76-82
	AK	P. Bellosta et al., "Cleavage of K-FGF produces a truncated molecule with increased biological activity and receptor binding affinity," The Journal of Cell Biology, Volume 121, 1993, pp. 705-13
	AL	J. Aikawa et al., "Asparagine-linked glycosylation of the rat leukemia inhibitory factor expressed by simian COS7 cells," Biosci. Biotechnol. Biochem., 1998, 62(7), pp. 1318-1325
	AN	

EXAMINER /Marianne Allen/

DATE CONSIDERED 07/31/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include cop. this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: June 15, 2006

ATTY DOCKET NO.
2006_0825ASERIAL NO.
NEWAPPLICANT
Toshikazu NAKAMURA et al.FILING DATE
June 15, 2006

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BB						
	BC						
	BD						
	BE						
	BF						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

/MA/	BG	S. Bjoern et al., "Human plasma and recombinant factor VII., Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine.)), The Journal of Biological Chemistry, June 1991, Vol. 226, No. 17, pp. 11051-11057
↓	BH	K. M. Davis-Fleische et al., "Site-directed Mutagenesis of Heparin-binding EGF-like Growth Factor (HB-EGF): Analysis of O-glycosylation Sites and Properties," Growth Factors, 2001, Vol. 19, pp. 127-143
	BI	K. Fukuda et al., "Functional Analysis of Sugar Chains on HGF Based on Deglycosylation," Seikagaku, August 2004, Vol. 76, No. 8, p. 1035, 4P-214
	BJ	E. Adachi et al., "Functional Analysis of Sugar Chains on NK4 (HGF antagonist/angiogenesis inhibitor)," Seikagaku, August 2004, Vol. 76, No. 8, p. 1103, 4P-622
	BK	
	BL	
	BN	

EXAMINER /Marianne Allen/

DATE CONSIDERED 07/31/2008